Latest news

InsightsJune 7, 2026

Top 10 Operational Bottlenecks Slowing AI Adoption in Pharma

Executive Summary Artificial intelligence has rapidly evolved from an emerging technology to a strategic capability across the pharmaceutical industry. Organizations...

CommercialJune 7, 2026

Lilly Licenses Hanmi’s Phase 2 GLP-2 Drug for Short Bowel Syndrome in Deal Worth Up to $1.26 Billion

Eli Lilly has entered a licensing agreement with South Korea’s Hanmi Pharm for sonefpeglutide, a Phase 2 glucagon-like peptide-2...

ClinicalJune 7, 2026

AZ Reports Phase 3 Emerald-3 Progression-Free Survival Benefit for Imfinzi and Imjudo in Unresectable HCC

AstraZeneca has reported new phase 3 results from its Emerald clinical trial program evaluating the combination of Imfinzi (durvalumab)...

ClinicalJune 7, 2026

Revolution & Summit Witness Share Surge As Experimental Cancer Drugs Perform in Trials

Shares of Revolution Medicines surged 20% in overnight trading on Sunday and gained another 7.3% to reach $169 during...

RegulatoryJune 4, 2026

After FDA takes firm stance on safety hazards, Fulcrum discontinues the SCD program and explores other options

After the FDA's tough stance on the modality following...

CommercialJune 4, 2026

Subtle Medical Gets $33M Series C Funding, Appoints New CEO

Radiology departments at hospitals continue to face significant capacity...

RegulatoryJune 4, 2026

FDA Issues Complete Response Letter for Cingulate’s ADHD Drug CTx-1301 Over Manufacturing Questions

Cingulate has received a complete response letter (CRL) from the U.S. Food and Drug Administration (FDA) for CTx-1301, its...

ClinicalJune 4, 2026

Phase 3 Trial Shows Obefazimod Achieves Clinical Remission in Ulcerative Colitis Patients

Abivax reported phase 3 maintenance data showing that its experimental oral ulcerative colitis treatment, obefazimod, achieved clinical remission rates...

InsightsJune 2, 2026

AI in Medical Affairs: How Pharma Is Becoming a Real-Time Scientific Intelligence System

Executive Summary Medical affairs is undergoing a structural transformation that goes far beyond digital enablement or workflow automation. It is...

InsightsJune 2, 2026

Are Pharmaceutical Companies Moving Too Fast With AI Adoption?

Executive Summary Artificial intelligence is rapidly becoming embedded across nearly...

CommercialJune 2, 2026

For CAR-T biotech InnocsAI, struggling Liminatus pays $320 million in equity

Liminatus Pharma, a company specializing in cancer immunotherapies, has...

ClinicalJune 2, 2026

After a phase 2 failure, Biogen ends Parkinson’s prospects with Denali

Biogen and Denali Therapeutics announced that their Parkinson's disease drug candidate failed to meet the primary endpoint of a...

RegulatoryJune 2, 2026

FDA Approves Datroway for First-Line Triple-Negative Breast Cancer in Certain Patients

The competition among TROP2-targeting therapies in first-line triple-negative breast cancer (TNBC) has intensified following the U.S. Food and Drug...

ClinicalJune 2, 2026